Patrick Daugherty Discusses Rush to Relist Ripple’s XRP Following Crypto Court Ruling
14 July 2023
Foley & Lardner LLP partner Patrick Daugherty is quoted in the Blockworks article, “Exchanges rush to relist XRP, but an SEC appeal is possible,” discussing the move by some cryptocurrency exchanges to relist Ripple’s XRP token following a partial summary judgement by a federal judge in favor of the company that held the asset is not a security when traded on exchanges.
Daugherty said the relistings were not surprising. “The SEC lost everything that mattered,” he stated. “The only part of the case that Ripple lost had nothing whatsoever to do with exchange trading.”
Daugherty noted, however, that there might be concerns around a potential appeal of the decision by the SEC. He added that the success of an appeal would be unlikely.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”